A Look Into Communication Services Sector Value Stocks

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the…

The Meaning Behind Value Stocks

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga Insights has compiled a list of value stocks in the communication services sector that may be worth watching:

  1. Sphere Entertainment (NYSE:SPHR) – P/E: 3.88
  2. SK Telecom Co (NYSE:SKM) – P/E: 9.62
  3. Verizon Communications (NYSE:VZ) – P/E: 7.63
  4. GD Culture Group (NASDAQ:GDC) – P/E: 0.21
  5. Liberty Latin America (NASDAQ:LILAK) – P/E: 9.88

This quarter, Sphere Entertainment experienced a decrease in earnings per share, which was $10.21 in Q4 and is now $1.9. SK Telecom Co’s earnings per share for Q2 sits at $0.63, whereas in Q1, they were at 0.57. This quarter, Verizon Communications experienced an increase in earnings per share, which was $1.21 in Q2 and is now $1.22. Most recently, the company reported a dividend yield of 6.91%, which has decreased by 0.87% from last quarter’s yield of 7.78%.

This quarter, GD Culture Group experienced a decrease in earnings per share, which was $-0.07 in Q2 and is now $-1.15. Liberty Latin America’s earnings per share for Q3 sits at $0.29, whereas in Q2, they were at 0.17.

The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

Total
0
Shares
Related Posts
Read More

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ:

ERNA

Read More

Pliant Therapeutics Earlier Announced Data From The Integris-IPF Phase 2a Trial Demonstrating Bexotegrast 320 Mg Was Well Tolerated And Achieved Statistically Significant FVC Increase In Patients With Idiopathic Pulmonary Fibrosis; Trial Met Primary An…

Pliant Therapeutics, Inc. (NASDAQ: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF).

PLRX